SAR 103168

Drug Profile

SAR 103168

Alternative Names: SAR103168

Latest Information Update: 29 Feb 2012

Price : $50

At a glance

  • Originator sanofi-aventis
  • Developer Sanofi
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Protein kinase inhibitors; STAT5 transcription factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Acute myeloid leukaemia

Most Recent Events

  • 08 Feb 2012 Discontinued - Phase-I for Acute myeloid leukaemia in USA (IV)
  • 25 Sep 2009 Phase-I clinical trials in Acute myeloid leukaemia in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top